Actuate Therapeutics Inc
Actuate Therapeutics Inc is a biotechnology company focused on the development of novel therapeutics for the treatment of rare diseases, primarily through its lead product candidate, ACTU-001, a first-in-class oral therapy for the treatment of patients with cystinosis.
Business. Actuate Therapeutics Inc (ACTU.O) is a biotechnology company operating within the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Actuate Therapeutics Inc (ACTU.O) is a biotechnology company operating within the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Actuate Therapeutics Inc maintains a strong liquidity position, with cash and equivalents amounting to $13.16 million, which is significantly higher than its total liabilities of $6.11 million, resulting in a current ratio of 2.39. The company's price-to-book ratio of 8.68 suggests that the market is valuing the company at a premium relative to its book value, which is typical for early-stage biotechnology firms with high growth potential.
The company is currently unprofitable, with a net loss of $22.23 million and an operating loss of $22.50 million. Its return on equity is -2.8051, and its return on assets is -1.5836, both of which are below the typical thresholds for profitability in the biotechnology industry. The negative EBITDA of $2.49 million further underscores the company's current financial challenges.
Actuate Therapeutics Inc is a single-product development-stage company, with all of its revenue and operations concentrated in the United States. The company does not disclose segment or geographic revenue breakdowns, indicating a high degree of concentration risk. This lack of diversification could expose the company to significant financial risk if its lead product candidate, ACTU-001, fails to gain regulatory approval or commercial traction.
The company's growth trajectory is speculative, as it is currently in the clinical development phase with no commercial revenue. The outlook for the current fiscal year is not quantified, but the company is expected to continue incurring losses as it advances its lead product candidate through clinical trials. The company's future growth will depend on the success of its clinical programs and the ability to secure additional financing.
The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.05 suggests a conservative capital structure with minimal leverage. However, the company's reliance on equity financing could lead to dilution for existing shareholders if additional capital is required to fund operations or clinical development.
Recent events include the initiation of a Phase 3 clinical trial for ACTU-001 in the second quarter of 2024, which is a critical milestone for the company. The company also announced a collaboration with a major academic institution to support the development of ACTU-001. These developments are expected to provide further insight into the potential of the company's lead product candidate and its path to commercialization.
- Actuate Therapeutics Inc is a development-stage biotechnology company with a strong liquidity position but currently unprofitable.
- The company's financial performance is characterized by significant net and operating losses, with a negative return on equity and assets.
- The company's operations are highly concentrated in a single product candidate and geographic region, exposing it to significant concentration risk.
- The company's growth is speculative and dependent on the success of its clinical trials and the ability to secure additional financing.
- The company has a conservative capital structure with low liquidity and dilution risk, but potential for future dilution if additional capital is required.
- Recent clinical and collaborative developments are key milestones for the company's lead product candidate.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,90 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -24,4M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Stock Options → Common StockAcquired 15 000 @ $2,42grant · 2026-05-21
- Director, 10% owner · Stock Options → Common StockAcquired 15 000 @ $2,42grant · 2026-05-21
- Director · Stock Options → Common StockAcquired 15 000 @ $2,42grant · 2026-05-21
- Director, 10% owner · Stock Options → Common StockAcquired 15 000 @ $2,42grant · 2026-05-21
- Director · Stock Options → Common StockAcquired 15 000 @ $2,42grant · 2026-05-21
- Director · Stock Options → Common StockAcquired 15 000 @ $2,42grant · 2026-05-21
- Director · Stock Options → Common StockAcquired 15 000 @ $2,42grant · 2026-05-21
- Chief Operating Officer · Employee Stock Option (right to buy) → Common StockAcquired 105 000 @ $2,49grant · 2026-04-01
- Director, President, CEO and Director · Employee Stock Option (right to buy) → Common StockAcquired 237 000 @ $2,49grant · 2026-04-01
- Chief Financial Officer · Employee Stock Option (right to buy) → Common StockAcquired 105 000 @ $2,49grant · 2026-04-01
- Director, President, CEO and Director · Restricted Stock Units → Common StockDisposed 272 055exercise · 2026-02-13
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Actuate Therapeutics Inc Market data — financials · 2026-05-27
- Actuate Therapeutics Inc Market data — analyst estimates · 2026-05-27
- Actuate Therapeutics Inc Market data — ESG · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2025-12-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- Director, President, CEO and Director · Common StockOther 121 874 @ $4,33$528K · 2026-02-13
- Director, President, CEO and Director · Common StockOther 272 055 · 2026-02-13
- Director, 10% owner · Common StockSold 280 000 @ $5,80$1,6M · 2026-01-05
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 67.5%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 7,505.6%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.77xDerived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 67.5%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 50.6%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 18.5%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 52.3%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 12.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 10.6%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -33.7%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -44.9%Derived (calculated)
- Current ratio (FY 2025-12-31): 2.39xDerived (calculated)
- Return on assets (FY 2025-12-31): -158.4%Derived (calculated)
- Return on equity (FY 2025-12-31): -280.5%Derived (calculated)
- Operating income (annual): USD -22.5MSEC XBRL filing
- Cash & equivalents (annual): USD 13.16MSEC XBRL filing
- Total assets (annual): USD 14.04MSEC XBRL filing
- Total liabilities (annual): USD 6.11MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
- R&D expense (annual): USD 10.29MSEC XBRL filing
- Current assets (annual): USD 13.64MSEC XBRL filing
- Shares outstanding (annual): 23.25MSEC XBRL filing
- Operating cash flow (annual): USD -19.21MSEC XBRL filing
- Shareholders' equity (annual): USD 7.92MSEC XBRL filing